


Shionogi Fiscal 2010 Snapshot

Consolidated Financial Highlights


	FY2008	FY2009	FY2010	FY2010
	Millions of yen			Thousands of U.S. dollars
For the year ended March 31:				
Net sales	¥ 227,512	¥ 278,503	¥ 282,350	\$ 3,395,671
Cost of sales	70,929	76,264	81,737	983,007
Selling, general and administrative expenses	124,568	149,801	153,721	1,848,719
Operating income	32,015	52,438	46,892	563,945
Income before income taxes and minority interests	30,786	58,541	33,135	398,497
Net income	15,661	38,626	20,027	240,854
Research and development expenses	52,822	51,808	50,921	612,399
Capital investments	10,875	12,547	17,967	216,079
As of March 31:				
Property, plant and equipment, net	¥ 71,812	¥ 62,448	¥ 70,221	\$ 844,510
Total assets	501,853	540,762	523,242	6,292,748
Total long-term liabilities	114,955	131,956	115,326	1,386,963
Total net assets	310,094	341,976	328,096	3,945,833
Working capital	125,920	183,834	177,118	2,130,102
	Yen			U.S. dollars
Per share amounts:				
Net income	¥ 46.75	¥ 115.33	¥ 59.80	\$ 0.72
Net assets	924.43	1,019.71	979.69	11.78
Dividends per share	28.00	36.00	40.00	0.48

* U.S. dollar figures have been calculated, for convenience only, at the rate of ¥83.15 = US\$1.00, the approximate rate of exchange on March 31, 2011.


Net Sales




Operating Income



Net Income




Total Assets / Total Net Assets




Third Medium-Term Business Plan

Financial Target for Fiscal 2014 (Consolidated)



Shionogi Medium- to Long-Term Vision and Basic Strategy



Goals for the next 10 years

Consolidated net sales:
¥600 billion

Operating margin:
More than 25%

Overseas net sales ratio:
More than 50%

SONG for the Real Growth

Speed
Quick decision and implementation

Open Mind
Flexible mind and out of box thinking

Never-Failing Passion
Persistent passion

Global Perspective
Higher and broader perspective

Main Achievements in Fiscal 2010

Domestic sales

- Expanded sales 4.2% year on year, despite the impact of drug price reductions.
- Sales of 8 strategic products increased 32.3% year on year.

Sales expansion

Crestor® royalty income

- Grew royalty income 28.5% year on year due to increased sales globally.

Continuous growth

R&D

- Started Phase III clinical trials of an anti-HIV drug in multiple locations around the world.
- Inked an agreement with GlaxoSmithKline to conduct joint research, development, and commercialization regarding cephem antibiotics targeting Gram-negative bacteria using Shionogi's in-house discoveries.
- Suspended development in the US and Europe of anti-obesity drug, continued development in Japan and accelerated development of back-up compounds.

Global development

Shionogi Inc.

- Sales declined in line with product lineup reshuffle due to escalating competition from generics and other factors.
- Integrated Atlanta office in New Jersey with a view to stabilizing performance from the next fiscal period.

Improvement and integration

Fiscal 2011 Targets

Domestic sales

- Focus on 8 strategic products
- Strengthen sales to hospitals
- Improve productivity per MR

Shionogi Inc.

- Achieve operational integration benefits and stable operations

Cost control

- Reduce cost of sales
- Rigorously prioritize selling & general expenses and manage expense budget according to changes in the business environment

Domestic sales

- Increase and enhance R&D pipeline by setting appropriate priorities.
- Main pipeline milestones
 - ⇒S-349572 : Completion of enrollment for global Phase III clinical trials.
 - ⇒Ospemifene : Filing of NDA following completion of bioequivalence study in the US.
 - ⇒S-297995 : Initiation of Phase IIb trials in Japan and the US.
 - ⇒S-707106 : Completion of Phase IIa trials in the US. Go/No-Go decision